SYGNIS Pharma AG announced today the discontinuation of its therapeutic R&D project KIBRA and the adaptation of its organisation to the new business activity.
WILEX AG today announced that its US subsidiary WILEX Inc., Cambridge, MA, USA, has entered into an exclusive distributor agreement with Immundiagnostik AG, Bensheim, Germany for the commercialisation of the serum HER- 2/neu and CA IX ELISA tests in Germany, Austria and Switzerland (D-A-CH region). Immundiagnostik AG is specialised in the development and production of innovative immunoassays and other analytical detection methods. Financial terms of the agreement were not disclosed.
SYGNIS Pharma AG announced today that the merger with X-Pol Biotech S.L. (X-Pol) is completed.
WILEX AG has agreed a package of restructuring measures with the company’s Supervisory Board. The Executive Management Board is reacting to the results of the Phase III ARISER study with RENCAREX®, which missed the primary endpoint. The measures are designed to tailor development activities to the remaining projects, reduce the risks inherent in the business model and lower operating costs substantially.
Agennix AG (Frankfurt Stock Exchange: AGX) today announced financial results for the third quarter and nine months ended September 30, 2012.
Agennix AG (Frankfurt Stock Exchange: AGX) today announced results from several clinical studies evaluating talactoferrin alfa (talactoferrin).
SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) today reports its financial results for the six months period ended September 30, 2012.
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He will replace Thomas Widmann, who has been Chairman of the Company since 2004.
SAP AG (NYSE: SAP) and MolecularHealth, a leader in clinico-molecular informaticsTM, today announced that they have joined forces to improve oncologists’ clinical decision- making and enhance the quality of care for cancer patients.
immatics biotechnologies GmbH, a biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, announced today that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma (RCC). The trial has completed patient inclusion and it is expected that around 345 patients will be randomized across 10 countries in the US and Europe. The first (interim) overall survival results are expected during the first half of 2014.
Apogenix, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, today announced that its lead product, Apocept™ (APG101), has been selected by Elsevier Business Intelligence and Windhover Conferences as one of oncology’s “Top 10 Projects To Watch”.
joimax® as the recognized pioneer in endoscopic spine surgery has launched the transforaminal access to the spinal canal under the brand name TESSYS® in 2004. Since then the company has consistently extended its product range and covers the complete array of therapies for spinal disorders with its systems today.
Cosmo Pharmaceuticals, (SIX:COPN), announced today that its phase II clinical trials program for the evaluation of the polyp and adenoma detection rate in patients undergoing full colonoscopy after colonic staining with Methylene Blue MMX® tablets attained all the objectives and has generated the information required to complete the design of the phase III clinical trials.
Trial did not meet its primary endpoint of median disease-free survival (DFS)
WILEX AG today announced that the Company has received the FDA’s (Food and Drug Administration) minutes of the Type C meeting held in September 2012.
AC Immune was named by FierceBiotech today as one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's tenth annual Fierce 15 selection.
immatics announces publication of IMA901 cancer vaccine data in Nature Medicine: immune response associates with longer survival
Paper highlights clinical and immunological activity of IMA901 in renal cell carcinoma (RCC)
IMA901 is currently being evaluated in a pivotal phase 3 randomized study in patients with RCC
SYGNIS reports financial results for fiscal year 2011/2012.
SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard); today reported results for the fiscal year 2011/2012 ending on March 31, 2012.2012/07/18: Sygnis Pharma AG.
SYGNIS Announces Proposed Combination of Business with GENETRIX’ subsidiary X-Pol.
SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard)and GENETRIX Life Sciences, A.B., announced today, that the biotechnology companies have signed a Term Sheet under which the companies propose to combine GENETRIX Life Sciences, A.B.’s DNA sequencing subsidiary X-Pol Biotech, S.L., (Madrid, Spain) and SYGNIS Pharma AG. Goal is to develop and market X-Pol Biotech, S.L.’s DNA sequencing technologies and products.
WILEX announces results of successful first half year 2012.
WILEX AG (ISIN DE0006614720/WL6/FWB) published its financial report for the first six months of the 2012 financial year (1 December 2011 – 31 May 2012) and reported on the status of the Group’s projects.
WILEX AG opts for further payment under the licence agreement with Prometheus.
The Executive Management Board of WILEX AG (ISIN DE0006614720/WL6/FSE) today resolved with the approval of the Supervisory Board to opt for a further cash payment according to the licence agreement with Prometheus Laboratories Inc. (Prometheus), San Diego, CA, USA, for the out-licensing of the marketing rights to RENCAREX ® (Girentuximab) in the United States.
AC Immune and Genentech Enter into Second Antibody Collaboration for Alzheimer’s Disease.
AC Immune SA, today announced that it has entered into a second exclusive worldwide license agreement and research collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for the research, development and commercialization of AC Immune’s anti-Tau antibodies for the potential treatment of Alzheimer’s disease and other neurodegenerative diseases.
immatics presents encouraging overall survival data from a phase 2 study in Advanced Colorectal Cancer at the ASCO Annual Meeting.
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that its phase 2 trial with IMA910 in patients with advanced colorectal cancer (CRC) showed significantly longer overall survival in comparison to a matched-pair analysis of patients from the recently published phase 3 MRC COIN trial.
Primary study endpoint of increasing percentage of patients reaching PFS6 by 100% was exceeded by a factor of five.
The biopharmaceutical company Apogenix GmbH announced today that results of the recently completed phase II clinical efficacy trial with APG101 for the treatment of Glioblastoma Multiforme (GBM) will be presented at the world’s largest oncology congress ASCO – the Annual Meeting of the American Society of Clinical Oncology - in Chicago on June 1, 2012.
AC Immune SA, today announced that the anti-Abeta antibody crenezumab will be tested in a first-ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer´s disease because of their genetic history.
Agennix AG (Frankfurt Stock Exchange: AGX), a biopharmaceutical company focused on developing novel therapies that have the potential to substantially lengthen and improve the lives of critically ill patients in areas of major unmet medical need, today announced financial results for the first quarter and three months ended March 31, 2012.
Novaliq GmbH, a drug delivery company focusing on difficult to dissolve substances for ophthalmic and dermatological applications, announced the conclusion of a round of financing talks resulting in €3.9 million.
Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today announced that shareholders elected CEO Mauro Ajani as Chairman, replacing Rolf Stahel, who did not stand for re-election due to statutory age limitation and newly elected Prof. Dr. Maria Grazia Roncarolo, Scientific Director of the San Raffaele Scientific Institute in Milan, Italy, to the board as an Independent Director.
MolecularHealth, a leader in clinico-molecular informatics ™, today announced that Stephan Brock, Ph.D., the company’s president, showcased the use of clinico-molecular informatics for oncology treatment decision support at the SWOG Spring 2012 Group Meeting in San Francisco.
Lonza and Agennix AG (Frankfurt Stock Exchange: AGX) announced today an agreement for the production of Agennix’s first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI), talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer (NSCLC).
Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today announced that it has signed a license agreement with a leading U.S. public pharmaceutical company granting it exclusive world-wide rights for the development and commercialization of Cosmo's new chemical entity CB-03-01, an investigational anti-androgen drug targeted at certain topical skin applications.
Agennix AG (Frankfurt Stock Exchange: AGX), a biopharmaceutical company focused on developing novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need, today announced financial results for the fourth quarter and fiscal year ended December 31, 2011.
MolecularHealth, a leader in clinico-molecular informatics™, today announced that Larry Lesko, Ph.D., F.C.P., former Director of the Office of Clinical Pharmacology within the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER), has joined the company as a scientific advisor.
DSM Pharmaceutical Products, the custom manufacturing business of Royal DSM N.V. (NYSE, Euronext: DSM KON), and Agennix AG (Frankfurt Stock Exchange: AGX), a biopharmaceutical company focused on developing novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need, announced that they have signed a new contract under which DSM will manufacture the oral Dendritic Cell Mediated Immunotherapy (DCMI) talactoferrin for Agennix at commercial levels in anticipation of positive Phase III clinical data and product approval.
The biopharmaceutical company ApogenixGmbH announced today that the phase II clinical efficacy trial with APG101 has met its primary endpoint in the 2nd line treatment of Glioblastoma Multiforme (GBM), following a six month follow up of the last patient treated.
WILEX AG (ISIN DE0006614720 / WL6 / FSE) today announced that the US Food and Drug Administration (FDA) approved the protocol amendment for the pivotal Phase III ARISER trial with RENCAREX® needed to cancel the interim analysis and perform the final analysis of disease free survival (DFS).
Cosmo Pharmaceuticals SpA, (SIX: COPN), today announced that its licensee Santarus, Inc. (NASDAQ: SNTS) has been notified by the U.S. Food and Drug Administration that it has accepted the submission of its New Drug Application (NDA) seeking market approval for UCERIS™ (budesonide) Tablets 9 mg for the induction of remission of mild to moderate active ulcerative colitis.
MolecularHealth, Inc., a leader in clinico-molecular informatics™, today announced the establishment of a five-year research collaboration agreement with the U.S. Food and Drug Administration (FDA) to evaluate and refine MolecularHealth’s Molecular Analysis of Side Effects (MASE), a software system intended to support mechanism-based drug safety assessment and prediction.
SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) today reports its financial results for the third quarter and the first nine months of the fiscal year 2011/2012 ended December 31, 2011.
WILEX AG (ISIN DE0006614720 / WL6 / FSE) today announced that it has been granted funding of up to EUR 2.6 million from the German Federal Ministry of Education and Research (BMBF) for the pre-clinical and clinical development of its PI3K inhibitor WX-037.
Agennix AG (Frankfurt Stock Exchange (Prime Standard): AGX/ISIN DE000A1A6XX4) announced that, upon the recommendation of the study Data Safety Monitoring Board (DSMB), the Company has stopped further enrollment and treatment in the Phase II/III OASIS trial with talactoferrin in severe sepsis.
The shareholders of WILEX AG (ISIN DE0006614720/WL6/FSE) exercised their subscription and oversubscription rights for all of the 3,201,928 new no-par value bearer shares for EUR 3.10 per share by the end of the subscription period on 30 January 2012.
After being granted approval by the German Federal Institute of Drugs and Medical Devices (BfArM), a clinical trial on the diagnostics of urea cycle defects is being launched at Heidelberg University Hospital, led by Prof. Dr. med. Prof. h.c. (RCH) Georg Friedrich Hoffmann.
MolecularHealth, a clinico-molecular informatics company, today announced the launch of Molecular Analysis of Side Effects (MASE), its flagship drug safety assessment and prediction tool that enables mechanism-based safety analysis for all drugs currently on the market, along with the identification of potential adverse events for drugs in development.
MolecularHealth, a clinico-molecular informatics company, today announced the commercialization and planned roll-out of two next generation product lines that translate patient- specific molecular and genomic data, clinical history and published scientific evidence into safer, more effective drug choices for patients.
The biopharmaceutical company Apogenix GmbH today announced that it has received an additional € 2.3 million BMBF grant (German Federal Ministry of Education and Research) for the further advancement of its lead substance APG101.